TP53 and cancer: Moreover, triptolide was demonstrated to suppress p53-dependent p21 induction and modulates the p53 transcriptional activity in a cancer-specific manner, leading to enhancement of CDDP-induced apoptosis in urothelial cancer cells with wild-type p53, but not in those with mutant p53 or normal human urothelium cells [50].